Literature DB >> 27993729

Modulation of signaling mechanisms in the heart by thioredoxin 1.

Narayani Nagarajan1, Shinichi Oka1, Junichi Sadoshima2.   

Abstract

Myocardial ischemia/reperfusion and heart failure are the major cardiac conditions in which an imbalance between oxidative stress and anti-oxidant mechanisms is observed. The myocardium has endogenous reducing mechanisms, including the thioredoxin (Trx) and glutathione systems, that act to scavenge reactive oxygen species (ROS) and reduce oxidized proteins. The Trx system consists of Trx, Trx reductase (TrxR), and an electron donor, NADPH, where Trx is maintained in a reduced state in the presence of TrxR and NADPH. Trx1, a major isoform of Trx, is abundantly expressed in the heart and exerts its oxidoreductase activity through conserved Cys32 and Cys35, reducing oxidized proteins through thiol disulfide exchange reactions. In this review, we will focus on molecular targets of Trx1 in the heart, including transcription factors, microRNAs, histone deactylases, and protein kinases. We will then discuss how Trx1 regulates the functions of its targets, thereby affecting the extent of myocardial injury caused by myocardial ischemia/reperfusion and the progression of heart failure.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-oxidant; Disulfide; Ischemia/reperfusion; Thioredoxin

Mesh:

Substances:

Year:  2016        PMID: 27993729      PMCID: PMC5462876          DOI: 10.1016/j.freeradbiomed.2016.12.020

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  70 in total

1.  A novel mouse model for the identification of thioredoxin-1 protein interactions.

Authors:  Michelle L Booze; Jason M Hansen; Peter F Vitiello
Journal:  Free Radic Biol Med       Date:  2016-09-14       Impact factor: 7.376

2.  Cysteine residues mediate high-affinity binding of thioredoxin to ASK1.

Authors:  Salome Kylarova; Dalibor Kosek; Olivia Petrvalska; Katarina Psenakova; Petr Man; Jaroslav Vecer; Petr Herman; Veronika Obsilova; Tomas Obsil
Journal:  FEBS J       Date:  2016-09-18       Impact factor: 5.542

3.  Postconditioning leads to an increase in protein S-nitrosylation.

Authors:  Guang Tong; Angel M Aponte; Mark J Kohr; Charles Steenbergen; Elizabeth Murphy; Junhui Sun
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-17       Impact factor: 4.733

Review 4.  Thioredoxin.

Authors:  A Holmgren
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

Review 5.  Redox regulation of cellular activation.

Authors:  H Nakamura; K Nakamura; J Yodoi
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Site-specific and redox-controlled S-nitrosation of thioredoxin.

Authors:  Katherine T Barglow; Charles G Knutson; John S Wishnok; Steven R Tannenbaum; Michael A Marletta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-17       Impact factor: 11.205

7.  Buried S-nitrosocysteine revealed in crystal structures of human thioredoxin.

Authors:  Andrzej Weichsel; Jacqueline L Brailey; William R Montfort
Journal:  Biochemistry       Date:  2007-02-06       Impact factor: 3.162

8.  Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats.

Authors:  Samson Mathews Samuel; Mahesh Thirunavukkarasu; Suresh Varma Penumathsa; Srikanth Koneru; Lijun Zhan; Gautam Maulik; Perumana R Sudhakaran; Nilanjana Maulik
Journal:  Circulation       Date:  2010-03-01       Impact factor: 29.690

Review 9.  Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum.

Authors:  Karin Przyklenk
Journal:  Drugs Aging       Date:  2011-05-01       Impact factor: 3.923

10.  REDOX reaction at ASK1-Cys250 is essential for activation of JNK and induction of apoptosis.

Authors:  Philippe J Nadeau; Steve J Charette; Jacques Landry
Journal:  Mol Biol Cell       Date:  2009-07-01       Impact factor: 4.138

View more
  18 in total

Review 1.  The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?

Authors:  Alexey A Tinkov; Geir Bjørklund; Anatoly V Skalny; Arne Holmgren; Margarita G Skalnaya; Salvatore Chirumbolo; Jan Aaseth
Journal:  Cell Mol Life Sci       Date:  2018-01-11       Impact factor: 9.261

2.  Thioredoxin-1 maintains mechanistic target of rapamycin (mTOR) function during oxidative stress in cardiomyocytes.

Authors:  Shin-Ichi Oka; Tsuyoshi Hirata; Wataru Suzuki; Daichi Naito; Yanbin Chen; Adave Chin; Hiroaki Yaginuma; Toshiro Saito; Narayani Nagarajan; Peiyong Zhai; Santosh Bhat; Kevin Schesing; Dan Shao; Yoko Hirabayashi; Junji Yodoi; Sebastiano Sciarretta; Junichi Sadoshima
Journal:  J Biol Chem       Date:  2017-09-22       Impact factor: 5.157

3.  Up-regulation of Thioredoxin 1 by aerobic exercise training attenuates endoplasmic reticulum stress and cardiomyocyte apoptosis following myocardial infarction.

Authors:  Mengxin Cai; Zujie Xu; Wenyan Bo; Fangnan Wu; Wenpu Qi; Zhenjun Tian
Journal:  Sports Med Health Sci       Date:  2020-07-31

4.  HAX-1 regulates SERCA2a oxidation and degradation.

Authors:  Philip A Bidwell; Guan-Sheng Liu; Narayani Nagarajan; Chi Keung Lam; Kobra Haghighi; George Gardner; Wen-Feng Cai; Wen Zhao; Luke Mugge; Elizabeth Vafiadaki; Despina Sanoudou; Jack Rubinstein; Djamel Lebeche; Roger Hajjar; Junichi Sadoshima; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2017-11-21       Impact factor: 5.000

Review 5.  Redox signaling, mitochondrial metabolism, epigenetics and redox active phytochemicals.

Authors:  Renyi Wu; Shanyi Li; Rasika Hudlikar; Lujing Wang; Ahmad Shannar; Rebecca Peter; Pochung Jordan Chou; Hsiao-Chen Dina Kuo; Zhigang Liu; Ah-Ng Kong
Journal:  Free Radic Biol Med       Date:  2020-12-24       Impact factor: 7.376

Review 6.  CD38: A Potential Therapeutic Target in Cardiovascular Disease.

Authors:  Wanyun Zuo; Na Liu; Yunhong Zeng; Yaozhong Liu; Biao Li; Keke Wu; Yunbin Xiao; Qiming Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-08       Impact factor: 3.727

7.  Nampt Potentiates Antioxidant Defense in Diabetic Cardiomyopathy.

Authors:  Shin-Ichi Oka; Jaemin Byun; Chun-Yang Huang; Nobushige Imai; Guersom Ralda; Peiyong Zhai; Xiaoyong Xu; Sanchita Kashyap; Junco S Warren; John Alan Maschek; Trevor S Tippetts; Mingming Tong; Sundararajan Venkatesh; Yoshiyuki Ikeda; Wataru Mizushima; Toshihide Kashihara; Junichi Sadoshima
Journal:  Circ Res       Date:  2021-04-30       Impact factor: 23.213

8.  Thioredoxin-1 Is a Target to Attenuate Alzheimer-Like Pathology in Diabetic Encephalopathy by Alleviating Endoplasmic Reticulum Stress and Oxidative Stress.

Authors:  Yu Guo; Chenghong Zhang; Chunyang Wang; Yufei Huang; Jingyun Liu; Haiying Chu; Xiang Ren; Li Kong; Haiying Ma
Journal:  Front Physiol       Date:  2021-05-17       Impact factor: 4.566

9.  Thioredoxin-1 maintains mitochondrial function via mechanistic target of rapamycin signalling in the heart.

Authors:  Shin-Ichi Oka; Adave Chin; Ji Yeon Park; Shohei Ikeda; Wataru Mizushima; Guersom Ralda; Peiyong Zhai; Mingming Tong; Jaemin Byun; Fan Tang; Yudai Einaga; Chun-Yang Huang; Toshihide Kashihara; Mengyuan Zhao; Jihoon Nah; Bin Tian; Yoko Hirabayashi; Junji Yodoi; Junichi Sadoshima
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 13.081

Review 10.  Sex differences in inflammation, redox biology, mitochondria and autoimmunity.

Authors:  Damian N Di Florio; Jon Sin; Michael J Coronado; Paldeep S Atwal; DeLisa Fairweather
Journal:  Redox Biol       Date:  2020-03-04       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.